China News Service, April 23 (Reporter Chen Jing) The reporter was informed on the 23rd that the "double AI" program of carrelizumab combined with apatinib has made breakthrough progress in the treatment of advanced liver cancer.

The related phase III clinical study led by Professor Shukui Qin is proceeding smoothly, and the study is initiated simultaneously in China, the United States and Europe.

　　This means that the "Double Ai" program will not only benefit Chinese liver cancer patients, but also bring good news to liver cancer patients worldwide.

Both carrelizumab and apatinib have indications for the treatment of advanced liver cancer.

Among them, carrelizumab is included in the national medical insurance and is an immunotherapy drug with liver cancer indications.

　　Survey data shows that more than 50% of liver cancer patients in the world are in China, and more than 80% of new patients each year have no chance of surgery.

The results of the RESCUE study showed that the ORR (objective effective rate) of the first-line treatment group of the "double AI" regimen was as high as 46%, and the 1-year OS (overall survival) rate was as high as 75%.

　　It is reported that the combination of apatinib and carrelizumab can fundamentally change the immune microenvironment, thereby achieving a "1+1>2" effect.

The results of a related multi-center phase II clinical study jointly led by Professor Qin Shukui from Nanjing Jinling Hospital and Professor Ren Zhenggang from Zhongshan Hospital of Fudan University showed that the mOS (median overall survival) of the carrelizumab group was 13.8 months; In the AHELP study of apatinib in the second-line treatment of liver cancer led by Professor Qin Shukui, the mOS (median overall survival) of the apatinib group was 8.7 months.

　　It is understood that the combination of immunotherapy and anti-angiogenesis targeted drugs has gradually become the standard treatment for advanced liver cancer.

The 2021 edition of the NCCN guidelines regards the combination of immunization and anti-angiogenesis targeted drugs as the first-line recommendation for the treatment of advanced liver cancer.

It is reported that NCCN refers to the National Comprehensive Cancer Network of the United States.

(Finish)